As­traZeneca nabs pri­or­i­ty re­view for Lyn­parza in prostate as PARP in­hibitors ex­pand to more can­cers

Lyn­parza keeps rolling.

Three weeks af­ter the FDA cleared the As­traZeneca drug as a first-line treat­ment of a par­tic­u­lar form of ad­vanced pan­cre­at­ic can­cer, the agency has grant­ed pri­or­i­ty re­view for the drug as a sec­ond-line treat­ment of a par­tic­u­lar form of ad­vanced prostate can­cer. A PDU­FA date is set for the sec­ond quar­ter of 2020.

The news is an­oth­er notch in the belt for an R&D pro­gram and an on­col­o­gy pipeline that was strug­gling just three years ago. Lyn­parza, a PARP in­hibitor, and Imfinzi, As­traZeneca’s CT­LA4 im­munother­a­py, will each fin­ish 2019 with over $1 bil­lion sales, and they on­ly con­tin­ue to ex­pand their po­ten­tial mar­ket. Last week, a Lyn­parza com­bo got pri­or­i­ty re­view for a form of ad­vanced ovar­i­an can­cer and yes­ter­day an Imfinzi com­bo earned or­phan des­ig­na­tion for liv­er can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER